Cabozantinib (Cabometyx) for the treatment of advanced renal cell cancer

Introduction

Cabozantinib (trade name: Cabometyx) has been approved in Germany since September 2016 for the treatment of advanced renal cell cancer in adults who have had treatment before. It has also been approved for first-line treatment since May 2018.

Renal cell cancer is the most common type of kidney cancer. It usually goes unnoticed for a long time as symptoms only occur in people with advanced, larger tumors. Symptoms include pain in the kidney area that may radiate into the back, as well as blood in urine. If renal cell cancer has already grown too much or spread to other organs, surgery to remove it may no longer be an effective treatment.

Some people with advanced renal cell cancer have a mutated protein in their tumor tissue, such as the vascular endothelial growth factor (VEGF) or the immunohistochemical hepatocyte growth factor. These mutated proteins may contribute to uncontrolled growth of the tumor.

Cabozantinib aims to block these proteins in the tumor tissue and inhibit tumor growth.

Application

Cabozantinib is available in tablet form in doses of 20, 40 and 60 mg. The recommended dose is 60 mg a day. The dosage depends on how well the patient tolerates the drug and on the side effects, and can be adapted individually. The treatment is stopped if the disease still progresses or if very severe side effects arise.

Other treatments

Medications such as bevacizumab with interferon alfa-2a, pazopanib, sunitinib, or temsirolimus are available for patients with advanced renal cell cancer who haven't had treatment before, depending on the outlook for the further course of their disease.

For people who have already had treatment aimed at VEGF, the standard treatment options are everolimus or nivolumab.

Assessment

In 2018, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) examined the advantages and disadvantages cabozantinib has in the treatment of advanced renal cell cancer compared with the standard treatments.

The manufacturer provided one relevant study each for the following groups:

  • Adults who haven not had treatment: Cabozantinib compared with sunitinib
  • Adults who have had treatment: Cabozantinib compared with everolimus

More information

This information summarizes the main results of reviews produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The reviews were commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the reviews and the hearings received, the G-BA passed a resolution on the added benefit of cabozantinib (Cabometyx).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Cabozantinib (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A17-56. January 11, 2018. (IQWiG reports; Volume 583).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Cabozantinib (renal cell carcinoma) – Addendum to Commission A17-56. Commission A18-13. March 09, 2018. (IQWiG reports; Volume 603).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Cabozantinib (renal cell carcinoma) – Addendum to Commission A17-56. Commission A18-18. March 15, 2018. (IQWiG reports; Volume 606).

Cabozantinib (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A18-37. XX.0X.2018. (IQWiG reports; Volume 6XX).

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Updated on October 4, 2018
Next planned update: 2021

Authors/Publishers:

Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.